dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Mallo, Maria del Mar |
dc.contributor.author | Tuechler, Heinz |
dc.contributor.author | Arenillas, Leonor |
dc.contributor.author | Raynaud, Sophie |
dc.contributor.author | Cluzeau, Thomas |
dc.contributor.author | Shih, Lee-Yung |
dc.contributor.author | Palomo Diaz, Laura |
dc.date.accessioned | 2023-05-25T07:38:06Z |
dc.date.available | 2023-05-25T07:38:06Z |
dc.date.issued | 2023-05 |
dc.identifier.citation | Mallo M, Tuechler H, Arenillas L, Raynaud S, Cluzeau T, Shih LY, et al. Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. EJHaem. 2023 May;4(2):446–9. |
dc.identifier.issn | 2688-6146 |
dc.identifier.uri | https://hdl.handle.net/11351/9617 |
dc.description | Chromosome; Cytogenetics; Myelodysplastic syndromes |
dc.description.abstract | Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20–30% with the complementary application of genomic microarrays. We here present a multicenter collaborative study of 163 MDS cases with a normal karyotype (≥10 metaphases) at diagnosis. All cases were analyzed with the ThermoFisher® microarray (either SNP 6.0 or CytoScan HD) for the identification of both copy number alteration(CNA) and regions of homozygosity (ROH). Our series supports that 25 Mb cut-off as having the most prognostic impact, even after adjustment by IPSS-R. This study highlights the importance of microarrays in MDS patients, to detect CNAs and especially to detect acquired ROH which has demonstrated a high prognostic impact. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | EJHaem;4(2) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Síndromes mielodisplàsiques - Aspectes genètics |
dc.subject | Síndromes mielodisplàsiques - Prognosi |
dc.subject.mesh | Myelodysplastic Syndromes |
dc.subject.mesh | Prognosis |
dc.title | Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/jha2.651 |
dc.subject.decs | síndromes mielodisplásicos |
dc.subject.decs | pronóstico |
dc.relation.publishversion | https://doi.org/10.1002/jha2.651 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Mallo M] MDS Research Group, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. Microarrays Unit, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. [Tuechler H] Boltzmann Institute for Leukaemia Research and Hematology, Vienna, Austria. [Arenillas L] Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, GRETNHE, IMIM (Hospital del Mar Research Institute), Barcelona, Spain. [Raynaud S, Cluzeau T] Hematology Department, Cote d’Azur University, CHU of Nice, Nice, France. [Shih LY] Division of Hematology, Chang Gung Memorial Hospital-Linkuo, Chang Gung University, Taoyuan City, Taiwan. [Palomo L] Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 37206269 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |